Table 2. Main characteristics related to liver disease in patients with COVID-19 infection in different Chinese regions based on a series of case reports.
| Author, Year | Country | Sample size (n) | Abnormal AST (%) | AST (IU/L) | Abnormal ALT (%) | ALT (IU/L) | Male, n (%) | Age (years) | Disease severity | History of liver diseases (%) | Drugs | |||
| Severe (%) | Non-severe (%) | Antibiotic drugs (%) | Antiviral drugs (%) | Antifungal drugs (%) | ||||||||||
| Guan WJ 202011 | China (Multi-center) | 1099 | 168 (22.2) | NA | 158 (21.3) | NA | 640 (58.2) | 47.0 (35.0–58.0) | 173 (15.7) | 926 (84.3) | 23 (2.1) | 632 (57.5) | 393 (35.8) | 30 (2.7) |
| Xu XW, 202012 | China (Zhejiang) | 62 | 10 (16.1) | 26 (20–32) | NA | 22 (14–34) | 36 (58.1) | 41.0 (32.0–52.0) | NA | NA | 7 (11.3) | 28 (45.2) | 55 (88.7) | NA |
| Chen NS, 20205 | China (Wuhan) | 99 | 35 (35.3) | 34 (26–48) | 28 (28.2) | 39 (22–53) | 67 (68.7) | 55.5 ± 35.1 | NA | NA | 11 (11.1) | 70 (70.7) | 75 (75.8) | 15 (15.2) |
| Chen L, 202013 | China (Wuhan) | 29 | 7 (24.1) | NA | 5 (17.2) | NA | 21 (72.4) | 56.0* | 14 (48.3) | 15 (51.7) | NA | NA | NA | NA |
| Wang DW, 202014 | China (Wuhan) | 138 | NA | 31 (24–51) | NA | 24 (16–40) | 75 (54.3) | 56.0 (42.0–68.0) | 36 (26.1) | 102 (73.9) | 4 (2.9) | 89 (64.5) | 124 (89.9) | NA |
| Pan F, 202015 | China (Wuhan) | 21 | NA | 32 ± 20 (15–95) | NA | 42 ± 31 (12–107) | 6 (28.6) | 40.0 ± 9.0 | 0 (0.0) | 21 (100.0) | NA | NA | NA | NA |
| Liu C, 202016 | China (Multi-center) | 32 | 2 (6.2) | 25 (19–32) | 9 (28.1) | 26 (17–46) | 20 (62.5) | 38.5 (26.3–45.8) | 4 (12.5) | 28 (87.5) | 1 (3.13) | NA | NA | NA |
| Huang C 202017 | China (Wuhan) | 41 | 15 (36.6) | 34 (26–48) | NA | 32 (21–50) | 30 (73.2) | 49.0 (41.0–58.0) | 13 (31.7) | 28 (68.3) | 1 (2.4) | 41 (100.0%) | 38 (92.7%) | NA |
| Chen HJ 202018 | China (Wuhan) | 9 | 3 (33.3) | 24 (21–119) | 3 (33.3) | 16 (11–58) | 0 (0) | 28 (26–34) | 0 (0.0) | 9 (100.0) | NA | 9 (100.0%) | 6 (66.7%) | NA |
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NA, not available. Liver diseases: any liver disease that can cause liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. Normal range for AST and ALT: AST < 40 IU/L and ALT < 40 IU/L.
*
Median, no interquartile range